"Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia," Cancer Cell (Vol: 22, Issue: 5, Page 656-667) - 2012
"Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2," Blood (Vol: 120, Issue: 14, Page 2853-2863) - 2012
"An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma," Biochemical and Biophysical Research Communications (Vol: 426, Issue: 3, Page 363-368) - 2012
"Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia," Leukemia (Vol: 26, Issue: 9, Page 2144-2146) - 2012
"In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia," Pediatric Blood and Cancer (Vol: 59, Issue: 3, Page 576-579) - 2012
"TSLP signaling network revealed by SILAC-based phosphoproteomics.," Molecular & cellular proteomics : MCP (Vol: 11, Issue: 6, Page M112.017764) - 2012
"TSLP signaling network revealed by SILAC-based phosphoproteomics," Molecular and Cellular Proteomics (Vol: 11, Issue: 6, Page ) - 2012
"JAK2 V617F down-modulates MPL," Blood (Vol: 119, Issue: 20, Page 4579-4580) - 2012
"Targeting survivin and p53 in pediatric acute lymphoblastic leukemia," Leukemia (Vol: 26, Issue: 4, Page 623-632) - 2012
"Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo," Oncology Letters (Vol: 3, Issue: 4, Page 807-815) - 2012
"p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC and FANCA-deficient mononuclear phagocytes," Blood (Vol: 119, Issue: 9, Page 1992-2002) - 2012
"Phosphoproteomics microarray screen reveals novel interaction between MPL and tensin2: Implications for biology, disease and therapeutics," Cell Cycle (Vol: 10, Issue: 16, Page 2621-2622) - 2011
"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies," Molecular Cancer Therapeutics (Vol: 10, Issue: 6, Page 1028-1035) - 2011
"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL T315I and exhibits a narrow resistance profile," Cancer Research (Vol: 71, Issue: 9, Page 3189-3195) - 2011
"CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability," Blood (Vol: 117, Issue: 2, Page 591-594) - 2011
"MET receptor sequence variants R970C and T992I lack transforming capacity," Cancer Research (Vol: 70, Issue: 15, Page 6233-6237) - 2010
"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms," Blood (Vol: 115, Issue: 25, Page 5232-5240) - 2010
"The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis," Leukemia (Vol: 24, Issue: 1, Page 226-229) - 2010
"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance," Cancer Cell (Vol: 16, Issue: 5, Page 401-412) - 2009
"RNAi screen for therapeutic target in leukemia," Cell Cycle (Vol: 8, Issue: 14, Page 2144-) - 2009
